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Stem Cell SelectStem cell biology covers a wide range of topics, as exemplified by the articles in this special review issue and
the papers highlighted in this Stem Cell Select. Understanding the interactions of stem cells with their
surroundings—whether they be Drosophila germ cells, human bone-forming precursors, or mouse immune
modulators—will reveal important target mechanisms that can be exploited therapeutically to promote
homing of stem cells to the correct location and to modulate stem cell fate in situ. Developing methods to
generate differentiated cells of a desired lineage from stem cells, such as muscle precursors, as well as iden-
tifying stem cell populations that give rise to unwanted populations, such as tumor cells, will also be key for
moving the field of regenerative medicine forward. To translate stem cell biology into therapeutic action will
necessitate that challenges be tackled from a range of angles using diverse animal model systems.
Jostling for Space in the Niche
Studies of Drosophila germ stem cells (GSCs) have provided an essential framework
for understanding how these cells interact with their niche, a model that has been
applied to other stem cells in a variety of lineages. In the Drosophila ovarium, female
GSCs exhibit E-cadherin-dependent binding to the cap cells, which constitute the
cellular component of their stem cell niche. Bone morphogenetic proteins (BMPs)
produced by the niche inhibit expression of the differentiation-inducing genes bam
and bgcn. Indeed, GSCs unable to express either of these proteins are blocked in
a stem cell-like state and have been shown to accumulate beyond points of cap
cell contact. In their new study, Ting Xie and colleagues (Jin et al., 2008) have used
bam and bgcnmutant flies to reveal that stem cells are, in fact, capable of competing
for physical contact with their niche. By clonally marking a fraction of existing GSCs
and calculating the relative loss of marked GSCs over time—which is consistent with
the expected turnover of GSCs during differentiation—the authors observed that
marked bgcn-mutant GSCs were more often retained in the niche relative to control
GSCs. More dramatically, niches became increasingly occupied with marked bam-
deficient GSCs over time, indicating that wild-type GSCs can be displaced entirely.
The mechanism behind the increased competitiveness of the bam and bgcn mutant
GSCs appears to involve E-cadherin, as the prolonged maintenance of bgcn-mutant
GSCs was overcome in compound mutant flies that also lacked E-cadherin expres-
sion. Furthermore, using either marked bam-deficient flies, or a model of heat-inducible bam overexpression, E-cadherin ac-
cumulation in the GSC-cap cell junction was inversely proportional to the levels of bam. Indeed, overexpression of E-cadherin
alone, in the absence of any bammutation, was sufficient to elevate the competitiveness of GSCs for contact with the niche.
The authors discuss the possibility that this competitive mechanism may offer a degree of ‘‘quality control’’ in maintaining an
adequate pool of competent stem cells. In addition, the observation that altered adhesion molecule expression can result in
stem cell replacement at an occupied niche offers an attractive model by which mammalian stem cells might be manipulated
to promote engraftment during therapeutic transplantation.
Z. Jin et al. (2008). Cell Stem Cell 2, 39–49.
Sweetening the Road Home
Before transplanted stem cells have an opportunity to compete for access to their niche, theymust first migrate, or ‘‘home,’’ to
the correct location. There is a long history of isolating bone-forming cells from cultures of bone marrow, both from mice as
well as from humans. However, the use of these populations for therapeutic bone formation is limited by their inability to home
to existing bone surfaces. Now, Sackstein and colleagues (2008) demonstrate that human bonemarrow-derived stromal cells
(also called ‘‘mesenchymal stem cells,’’ or MSCs) can be manipulated ex vivo such that they become competent to home to
endosteal surfaces via the marrow and to deposit human osteoid (bone-forming material) when transplanted into murine
recipients. Migration of blood cells is a well-studied process that involves the sequential interaction of adhesion molecules
and chemokines with their corresponding receptors. One particularly important ligand present on marrow endothelium is
E-selectin, which binds to multiple receptors, including a particular sialofucosylated glycoform of CD44 termed HCELL.
The authors demonstrate that cultures of MSCs, which do not normally express HCELL, instead express high levels of a sia-
lylated form of CD44. By developing a novel technique to modify surface glycans without impacting cell viability or function,
the authors were able to generate human MSCs that expressed HCELL. These modified cells, capable of binding specifically
to E-selectin in vitro, were transplanted intravenously into mice and tracked using real-time confocal microscopy of the bone
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marrow cavities in the skulls of recipients. The authors demonstrate that the HCELL+ MSCs home to sinusoidal vessels in the
marrow and infiltrate the marrow parenchyma. Despite the HCELL modification being stable in culture for only 24 hr, exam-
ination of the MSC-injected animals revealed HCELL-dependent migration to endosteal surfaces within 10 days and subse-
quent bone-forming human osteoid deposits 12 weeks post-transplantation. The results of this study provide not only an
important advance in the delivery of functionally relevant bone-forming cells but also open avenues to new methods for
the manipulation of the migration patterns of other adoptively transferred cell populations.
R. Sackstein et al. (2008). Nat. Med. 14, 181–187.
T Cells: Moths to an MSC Flame
Adherent stromal cells derived from many tissues, particularly bone marrow, can be expanded in culture and will generate
differentiated progeny in response to a variety of in vitro protocols. In addition to forming bone, as in the Sackstein et al. paper,
these MSC populations tend to home to sites of inflammation when transplanted. In addition, this migration often, but not
always, correlates with improved regeneration/repair at the site of injury. The mechanism of action behind the observed re-
covery remains largely open to question; however, a growing body of evidence points toMSC-mediated immune suppression
being responsible for their therapeutic effect. Recent work from Yufang Shi’s laboratory (Ren et al., 2008) outlines at least one
mechanism by which MSCs appear to suppress T cell-mediated immune responses. The authors used clonal murine MSC
lines and combined a series of in vitro assays to demonstrate that T cell proliferation could be blocked in the presence of
MSCs, provided IFN-g and at least one of three inflammatory cytokines (TNFa, IL-1a, or IL1-b) were also present. These com-
binations of cytokines induced MSCs to produce nitric oxide synthase, iNOS, and resulted in production of very high levels of
NO, which were required for the T cell-suppressive effect. By an independent mechanism, the same inflammatory cocktails
induced cultured MSCs to secrete multiple chemokines, and the authors suggest that this effect is likely responsible for the
observed migration of activated T cells towards the treated MSCs. Strikingly, using transplanted iNOS/MSCs or blocking
antibodies against inflammatory cytokines inmousemodels of acute, localized, or chronic systemic inflammation, the authors
demonstrate that MSC-derived NO may be responsible for the T cell-suppressive effect in vivo. With this study, the authors
offer important insight into the pathways responsible for the therapeutic benefit observed in some cases of MSC transplan-
tation. With an improved handle on the mechanisms involved in MSC-mediated effects, therapies can be tailored to a given
clinical situation.
G. Ren et al. (2008). Cell Stem Cell 2, 141–150.
Muscling in on the Therapeutic Action
In order to harness the therapeutic potential of embryonic stem (ES) cells, many hur-
dles will need to be overcome. Prominent among these challenges are the generation
of specific differentiated cells of interest and development of protocols with which to
transfer the resulting population such that the cells engraft and contribute to the target
tissue in a patient. In a new study, Darabi and colleagues (2008) demonstrate that
functional skeletal muscle can be generated after the transfer of differentiated ES cells
into two different mouse models of muscle injury. Historically, myogenic cells have
been difficult to obtain from ES cell cultures. In this study, the authors engineered
an ES cell line to carry an inducible construct controlling expression of Pax3, a tran-
scription factor known to promote the expression of myogenic regulatory genes. By
inducing the Pax3 construct with doxycycline, cultured ES cells gave rise to popu-
lations with phenotypic and gene expression profiles consistent with myogenic pro-
genitors. However, transfer of unfractionated cultures to cardio-toxin injured muscles
in murine hosts resulted in teratoma formation, indicative of residual undifferentiated
cells present in the transferred cell population. By preselecting a population of
PDGFaR+Flk-1 cells, the authors were able to obtain significant in vivo muscle
generation and no tumor growth after transplantation. The authors went on to test whether these ES cell-derived myogenic
progenitors could contribute functionally to muscle after engraftment. When the Pax3-induced PDGFaR+Flk-1 cells were
injected locally or systemically into mdx mice (a model of human muscular dystrophy), there was a boost in the contractile
properties of the dystrophicmuscles. The potential to generate cells withmyogenic capacity in culture and systemically trans-
fer them to recipients is an important step towards the therapeutic application of ES cell-derived cells. Remaining challenges
include improving the level of engraftment so as to achieve further functional recovery and development of a protocol to yield
similar populations of human cells.
R. Darabi et al. (2008). Nat. Med. 14, 134–143.
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Pinpointing the Cancer Culprit
The cancer stem cell hypothesis proposes that bulk tumor populations harbor a sub-
fraction of cells with the potential to generate all other cell types present in the tumor,
and that these so-called cancer stem cells (CSCs) are self-replicating such that they
retain the capacity to generate additional tumors in a serial fashion. Whereas some
studies erroneously designate populations as CSCs based only on surface marker
phenotype and/or the capacity to grow in vitro, two recent papers provide ample
evidence to support their claims of isolating tumor-initiating populations in human
melanoma and liver cancer (Schatton et al., 2008 and Yang et al., 2008, respectively).
In the first case, the Frank laboratory demonstrated that the tumor-forming capacity of
human melanoma samples was highly enriched in the subpopulation expressing
a protein involved in chemoresistance, ABCB5, the frequency of which in a given
sample correlated with escalating clinical progression. Transplantation of purified
cells led to dose-dependent tumor formation in immune-compromised mice. Serially
passaged repurified primary tumor ABCB5+ cells harbored tumor-initiating activity at
a frequency of 1 in 120,000 cells. Dramatically, systemic injection of an ABCB5-
targeted antibody into murine hosts was sufficient to significantly reduce the tumor burden of established tumors derived
from primary patient samples. Meanwhile, in a related but independent study, Yang et al. (2008) performed similarly rigorous
analyses of human liver cancer cell lines and primary tumor samples from patients. They discovered that the CD90+ fraction
contained tumor-forming potential when injected intomurine hosts at limiting dilutions and could bemaintained for three serial
passages in vivo. In addition, theCD90+ population could be further fractionated according to CD44 expression, and systemic
injection of a CD44-specific antibody was sufficient to prevent the growth of both primary andmetastatic liver tumors induced
by purified CD90+ populations. The authors also detected CD90+ tumor-forming cells in patient blood samples, the frequency
of which correlated with tumor burden, suggesting that screening blood samples from cancer patients might prove useful for
monitoring disease progression. These two studies add to the growing body of literature suggesting that identification of
tumor-initiating populations may advance the development of new and effective cancer therapies.
T. Schatton et al. (2008). Nature 451, 345–349.
Z.F. Yang et al. (2008). Cancer Cell 13, 153–166.
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